Overview

Effects of a Dexmedetomidine on Quality of Recovery 40 and Postoperative Nausea and Vomiting in Breast Cancer Surgery

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
0
Participant gender:
Female
Summary
Postoperative nausea and vomiting (PONV) is common following beast surgery. Dexmedetomidine was reported to a reduced PONV due to opioid-sparing effect. It is not clear if dexmedetomidine itself is useful on reducing PONV. The hypothesis of present study: intraoperative application of single dose dexmedetomidine (0.5 mcg/kg) is is effective than placebo for reducing of PONV and improve postoperative quality of recovery score within 48 postoperative hours.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yonsei University
Treatments:
Dexmedetomidine
Criteria
Inclusion Criteria:

- ASA I, II

- aged 20-70 years

- Undergoing breast cancer surgery

Exclusion Criteria:

- CAOD

- Bradycardia

- QT prolongation